Orally disintegrating selegiline for the treatment of Parkinson's disease

Bibliography

• de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45(12):2143-6
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6):1214-20
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5(3):235-45
   PubMed Web of Science ®Google Scholar
• Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 2005;11(Suppl 1):S3-7
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339(15):1044-53
   Google Scholar
• Birkmayer W, Hornykiewicz O. L-3,4-dioxyphenylalanin (=DOPA) Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961;73:787-8
   PubMedGoogle Scholar
• Lopez-Munoz F, Alamo C, Juckel G, Assion HJ. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I. Monoamine oxidase inhibitors. J Clin Psychopharmacol 2007;27(6):555-9
   PubMed Web of Science ®Google Scholar
• Zetzel L, Kaplan H. Liver damage concurrent with iproniazid administration. N Engl J Med 1958;258(24):1209-11
   PubMedGoogle Scholar
• Spellberg MA, Frankel JJ. Hepatic and renal damage with azotemia associated with iproniazid administration. Am J Gastroenterol 1962;37:64-9
   PubMedGoogle Scholar
• Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963;2(7313):849-50
   PubMed Web of Science ®Google Scholar
• Hutchison JC, Kinlaw WB. Tranylcypromine and reaction to cheese. Curr Ther Res Clin Exp 1964;6:127-9
   PubMedGoogle Scholar
• Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006;147(Suppl 1):S287-96
   PubMed Web of Science ®Google Scholar
• Knoll J, Ecseri Z, Kelemen K, et al. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965;155(1):154-64
   PubMedGoogle Scholar
• Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408
   PubMedGoogle Scholar
• Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 1975;36(3-4):303-26
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985;64(2):113-27
   PubMed Web of Science ®Google Scholar
• Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38(5):771-7
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328(3):176-83
   PubMed Web of Science ®Google Scholar
• Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245(4917):519-22
   PubMed Web of Science ®Google Scholar
• Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998;51(2):520-5
   PubMedGoogle Scholar
• Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33(2):91-102
   PubMed Web of Science ®Google Scholar
• Haberle D, Szoko E, Magyar K. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 2002;9(1):47-51
   PubMed Web of Science ®Google Scholar
• Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63(2):228-34
   PubMed Web of Science ®Google Scholar
• Yasar S, Goldberg JP, Goldberg SR. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl 1996;48:61-73
   PubMedGoogle Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008;23(6):784-9
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007;29(9):1825-49
   PubMed Web of Science ®Google Scholar
• Myllyla VV, Sotaniemi KA, Aasly J, Sjaastad O, Rinne U, McIntyre T, et al. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease. Adv Neurol 1993;60:676-80
   PubMedGoogle Scholar
• The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996;40(1):99-107
   PubMed Web of Science ®Google Scholar
• Virely P, Yarwood R. Zydis: a novel, fast dissolving dosage form. Manuf Chem 1990;(61):36-7
   Google Scholar
• Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110(11):1241-55
   PubMed Web of Science ®Google Scholar
• Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994;56(6 Pt 2):742-9
   PubMed Web of Science ®Google Scholar
• Youdim MB, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect 1993;91(2-3):181-95
   PubMedGoogle Scholar
• Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse 1994;18(2):86-93
   PubMed Web of Science ®Google Scholar
• Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997;25(6):657-62
   PubMed Web of Science ®Google Scholar
• Hidestrand M, Oscarson M, Salonen JS, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 2001;29(11):1480-4
   PubMed Web of Science ®Google Scholar
• Yasar S, Justinova Z, Lee SH, et al. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]. J Pharmacol Exp Ther 2006;317(1):387-94
   PubMedGoogle Scholar
• Mytilineou C, Leonardi EK, Radcliffe P, et al. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther 1998;284(2):700-6
   PubMedGoogle Scholar
• Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 1997;68(1):434-6
   PubMedGoogle Scholar
• Mizuta I, Ohta M, Ohta K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000;279(3):751-5
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60
   PubMed Web of Science ®Google Scholar
• Teravainen H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990;81(4):333-6
   PubMedGoogle Scholar
• Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992;42(2):339-43
   PubMed Web of Science ®Google Scholar
• Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 1993;8(Suppl 1):S36-40
   Google Scholar
• Mally J, Kovacs AB, Stone TW. Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. J Neurol Sci 1995;134(1-2):143-5
   PubMedGoogle Scholar
• Movement Disorder Society. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord 2002;17(Suppl 4):S38-44
   Web of Science ®Google Scholar
• Przuntek H, Kuhn W. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural Transm Suppl 1987;25:97-104
   PubMedGoogle Scholar
• Sivertsen B, Dupont E, Mikkelsen B, et al. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurol Scand Suppl 1989;126:147-52
   PubMedGoogle Scholar
• Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995;311(7020):1602-7
   PubMed Web of Science ®Google Scholar
• Larsen JP, Boas J. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian–Danish 5-year study. Norwegian-Danish Study Group. Mov Disord 1997;12(2):175-82
   PubMedGoogle Scholar
• Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2(8042):791-5
   PubMed Web of Science ®Google Scholar
• Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. NY State J Med 1987;87(12):646-9
   PubMedGoogle Scholar
• Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11(1):45-55
   PubMed Web of Science ®Google Scholar
• Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 2003;110(11):1257-71
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19(4):426-32
   PubMed Web of Science ®Google Scholar
• Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and ‘wearing off’ symptoms. Clin Neuropharmacol 2007;30(5):295-300
   PubMed Web of Science ®Google Scholar
• Lew MF, Pahwa R, Leehey M, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’ episodes in patients with Parkinson's disease. Curr Med Res Opin 2007;23(4):741-50
   PubMed Web of Science ®Google Scholar
• Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6(2):151-6
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005;45(8):878-94
   PubMed Web of Science ®Google Scholar
• Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004;355(3):169-72
   PubMed Web of Science ®Google Scholar
• Poewe W. The need for neuroprotective therapies in Parkinson's disease. Neurology 2006;66(Suppl 4):S2-9
   Google Scholar